Out of the black box

Treatment of resistant depression in adolescents and the antidepressant controversy

Karen Wagner, Joan Rosenbaum Asarnow, Benedetto Vitiello, Gregory Clarke, Martin Keller, Graham J. Emslie, Neal Ryan, Giovanna Porta, Satish Iyengar, Louise Ritz, Jamie Zelanzny, Matthew Onorato, David Brent

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The purpose of this article is to describe the effects of the pediatric antidepressant controversy on the Treatment of Serotonin-Selective Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents, ages 12-18 years, with SSRI resistant depression were randomized to one of four treatments for a 12 week trial: Switch to different SSRI, switch to an alternate antidepressant (venlafaxine), switch to an alternate SSRI plus cognitive behavior therapy (CBT), or switch to venlafaxine plus CBT. Results: The health advisories and "black box" warnings regarding suicidality and antidepressants in adolescents occurred during the course of the TORDIA trial. Revisions to the protocol, multiple-consent form changes, and re-consenting of patients were necessary. Recruitment of participants was adversely affected. Conclusion: Despite a cascade of unforeseen events that delayed the completion of the study, the TORDIA trial resulted in clinically important information about treatment-resistant depression in adolescents.

Original languageEnglish (US)
Pages (from-to)5-10
Number of pages6
JournalJournal of Child and Adolescent Psychopharmacology
Volume22
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Treatment-Resistant Depressive Disorder
Serotonin Uptake Inhibitors
Antidepressive Agents
Cognitive Therapy
Drug Labeling
Depression
Consent Forms
Pediatrics
Health
Therapeutics
Venlafaxine Hydrochloride

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Out of the black box : Treatment of resistant depression in adolescents and the antidepressant controversy. / Wagner, Karen; Asarnow, Joan Rosenbaum; Vitiello, Benedetto; Clarke, Gregory; Keller, Martin; Emslie, Graham J.; Ryan, Neal; Porta, Giovanna; Iyengar, Satish; Ritz, Louise; Zelanzny, Jamie; Onorato, Matthew; Brent, David.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 22, No. 1, 01.02.2012, p. 5-10.

Research output: Contribution to journalArticle

Wagner, K, Asarnow, JR, Vitiello, B, Clarke, G, Keller, M, Emslie, GJ, Ryan, N, Porta, G, Iyengar, S, Ritz, L, Zelanzny, J, Onorato, M & Brent, D 2012, 'Out of the black box: Treatment of resistant depression in adolescents and the antidepressant controversy', Journal of Child and Adolescent Psychopharmacology, vol. 22, no. 1, pp. 5-10. https://doi.org/10.1089/cap.2011.0045
Wagner, Karen ; Asarnow, Joan Rosenbaum ; Vitiello, Benedetto ; Clarke, Gregory ; Keller, Martin ; Emslie, Graham J. ; Ryan, Neal ; Porta, Giovanna ; Iyengar, Satish ; Ritz, Louise ; Zelanzny, Jamie ; Onorato, Matthew ; Brent, David. / Out of the black box : Treatment of resistant depression in adolescents and the antidepressant controversy. In: Journal of Child and Adolescent Psychopharmacology. 2012 ; Vol. 22, No. 1. pp. 5-10.
@article{04c261de573f4662954e2280eca57baf,
title = "Out of the black box: Treatment of resistant depression in adolescents and the antidepressant controversy",
abstract = "Objective: The purpose of this article is to describe the effects of the pediatric antidepressant controversy on the Treatment of Serotonin-Selective Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents, ages 12-18 years, with SSRI resistant depression were randomized to one of four treatments for a 12 week trial: Switch to different SSRI, switch to an alternate antidepressant (venlafaxine), switch to an alternate SSRI plus cognitive behavior therapy (CBT), or switch to venlafaxine plus CBT. Results: The health advisories and {"}black box{"} warnings regarding suicidality and antidepressants in adolescents occurred during the course of the TORDIA trial. Revisions to the protocol, multiple-consent form changes, and re-consenting of patients were necessary. Recruitment of participants was adversely affected. Conclusion: Despite a cascade of unforeseen events that delayed the completion of the study, the TORDIA trial resulted in clinically important information about treatment-resistant depression in adolescents.",
author = "Karen Wagner and Asarnow, {Joan Rosenbaum} and Benedetto Vitiello and Gregory Clarke and Martin Keller and Emslie, {Graham J.} and Neal Ryan and Giovanna Porta and Satish Iyengar and Louise Ritz and Jamie Zelanzny and Matthew Onorato and David Brent",
year = "2012",
month = "2",
day = "1",
doi = "10.1089/cap.2011.0045",
language = "English (US)",
volume = "22",
pages = "5--10",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Out of the black box

T2 - Treatment of resistant depression in adolescents and the antidepressant controversy

AU - Wagner, Karen

AU - Asarnow, Joan Rosenbaum

AU - Vitiello, Benedetto

AU - Clarke, Gregory

AU - Keller, Martin

AU - Emslie, Graham J.

AU - Ryan, Neal

AU - Porta, Giovanna

AU - Iyengar, Satish

AU - Ritz, Louise

AU - Zelanzny, Jamie

AU - Onorato, Matthew

AU - Brent, David

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Objective: The purpose of this article is to describe the effects of the pediatric antidepressant controversy on the Treatment of Serotonin-Selective Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents, ages 12-18 years, with SSRI resistant depression were randomized to one of four treatments for a 12 week trial: Switch to different SSRI, switch to an alternate antidepressant (venlafaxine), switch to an alternate SSRI plus cognitive behavior therapy (CBT), or switch to venlafaxine plus CBT. Results: The health advisories and "black box" warnings regarding suicidality and antidepressants in adolescents occurred during the course of the TORDIA trial. Revisions to the protocol, multiple-consent form changes, and re-consenting of patients were necessary. Recruitment of participants was adversely affected. Conclusion: Despite a cascade of unforeseen events that delayed the completion of the study, the TORDIA trial resulted in clinically important information about treatment-resistant depression in adolescents.

AB - Objective: The purpose of this article is to describe the effects of the pediatric antidepressant controversy on the Treatment of Serotonin-Selective Reuptake Inhibitor (SSRI) Resistant Depression in Adolescents (TORDIA) trial. Method: Adolescents, ages 12-18 years, with SSRI resistant depression were randomized to one of four treatments for a 12 week trial: Switch to different SSRI, switch to an alternate antidepressant (venlafaxine), switch to an alternate SSRI plus cognitive behavior therapy (CBT), or switch to venlafaxine plus CBT. Results: The health advisories and "black box" warnings regarding suicidality and antidepressants in adolescents occurred during the course of the TORDIA trial. Revisions to the protocol, multiple-consent form changes, and re-consenting of patients were necessary. Recruitment of participants was adversely affected. Conclusion: Despite a cascade of unforeseen events that delayed the completion of the study, the TORDIA trial resulted in clinically important information about treatment-resistant depression in adolescents.

UR - http://www.scopus.com/inward/record.url?scp=84857300110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857300110&partnerID=8YFLogxK

U2 - 10.1089/cap.2011.0045

DO - 10.1089/cap.2011.0045

M3 - Article

VL - 22

SP - 5

EP - 10

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1

ER -